ArticleJCEM case reports2025
Intrathyroidal Fifth Parathyroid Adenoma: A Rare Cause of Primary Hyperparathyroidism.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiofrequency ablation as an alternative treatment for hyperparathyroidism: a case study of a single parathyroid adenoma and review of the literature.Hormones (Athens, Greece) · 2026Review
- Primary hyperparathyroidism: targeted, focused exploration with "selective" parathyroidectomy : Minimally invasive open vs. minimally invasive video-assisted vs. endoscopic approach.Wiener klinische Wochenschrift · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 53-year-old female patient was incidentally found to have asymptomatic hypercalcemia, later diagnosed due to primary hyperparathyroidism (PHPT): ionized calcium 6.48 mg/dL (SI: 1.62 mmol/L) (reference range, 4.48-5.28 mg/dL [SI: 1.12-1.32 mmol/L]); total calcium 12.08 mg/dL (SI: 3.02 mmol/L) (reference range, 8.8-10.4 mg/dL [SI: 2.20-2.60 mmol/L]); and parathyroid hormone (PTH) 184.8 pg/mL (SI: 19.6 pmol/L) (reference range, 15-85 pg/mL [SI: 1.6-9.0 pmol/L]). Preoperatively, standard imaging modalities, including ultrasound (US), four-dimensional computed tomography (4DCT) and dual radiolabeled technetium-99 pertechnetate and sesta-methoxyisobutylisonitrile with single photon emission computed tomography (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.